| DB ID | MyCo_3299 |
| Title | Increased sensitivity to IL-4 in patients with allergic bronchopulmonary aspergillosis |
| Year | 2000 |
| PMID | 11146389 |
| Fungal Diseases involved | Allergic bronchopulmonary aspergillosis |
| Associated Medical Condition | None |
| Genus | Aspergillus |
| Species | fumigatus |
| Organism | Aspergillus fumigatus |
| Ethical Statement | Patient involvement in the study was approved by the St. Louis University Institutional Review Board. |
| Site of Infection | None |
| Opportunistic invasive | None |
| Sample type | Body fluid |
| Sample source | Blood |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | CD86 |
| Biomarker Full Name | CD86 |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | USA |
| Cohort | Three groups of patients, ABPA, atopic and nonatopic, were studied , there were 10 patients with ABPA, 4 with asthma and 6 with CF. |
| Cohort No. | 20 |
| Age Group | Aug-76 |
| P Value | p<0.001 |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Allergic bronchopulmonary aspergillosis (ABPA) is a hypersensitivity lung disease mediated by an allergic late- phase inflammatory response to Aspergillus fumigatus antigens characterized by markedly elevated A. fumigatus-specific and total IgE levels and eosinophilia, and manifested by wheezing, pulmonary infiltrates and pul- monary bronchiectasis and fibrosis. Previously we reported that there was an IL-4-dependent autocrine Th2 CD4+ T cell response to an Aspergillus allergen, Asp f 1. In addition, ABPA patients’ B cells spontaneously synthesized and secreted IgE. Recently, immunogenet- ics studies implicating HLA-DR2 and DR5 restriction have further contributed to the understanding of the immunopathogenesis of why certain individuals are sus- pectible to develop ABPA. However, ABPA afflicts only a small percentage of susceptible atopic individuals with either asthma or cystic fibrosis. |
| Technique | Analytic |
| Analysis Method | Flow Cytometry Analysis |
| ELISA kits | None |
| Assay Data | None |
| Validation Techniques used | ELISA, Flow Cytometry Analysis |
| Up Regulation Down Regulation | Increase |
| Sequence Data | None |
| External Link | None |
